Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.3c00322
Abstract: Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened… read more here.
Keywords: ruthenium; combination therapy; cancer combination; olaparib synergy ... See more keywords
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Sign Up to like & getrecommendations! Published in 2023 at "Theranostics"
DOI: 10.7150/thno.80091
Abstract: Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity.… read more here.
Keywords: combination therapy; therapy; strategies targeting; associated opportunities ... See more keywords